ArticleStem cell reports2025
Characterizing hypoxia-orchestrated post-stroke changes in oligodendrocyte precursor cells for optimized cell therapy.
Article in Stem cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- In situ structure of the human ciliary transition zone links linker defects to primary ciliary dyskinesia.Science (New York, N.Y.) · 2026Article
- Recombinant CXCL16 reduces brain injury by modulating microglial phenotype and attenuating apoptosis in acute ischemic stroke.Scientific reports · 2026Article
- Analytical Methods and Application of Single-Cell and Single-Nucleus Transcriptomics in the Study of Ischemic Stroke.Biomolecules · 2026Review
- High-altitude hypoxic cues and cerebral ischemic tolerance: an evidence-graded translational framework for stroke research.Frontiers in neuroscience · 2026Review
- Inflammation-centered neurovascular-immune-metabolic remodeling in ischemic stroke: stage-dependent mechanisms, regulated cell death, and therapeutic translation.Frontiers in immunology · 2026Review
- Single-cell and single-nucleus transcriptomics in ischemic stroke: cellular mechanisms and therapeutic implications.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligodendrocyte precursor cells (OPCs) are highly adaptable, engaging in diverse functions beyond myelination. However, how OPCs adjust their roles after ischemic stroke and contribute to recovery remains largely unknown. To address this gap, we constructed a "transient middle cerebral artery occlusion (tMCAO) atlas" by integrating mouse single-cell RNA sequencing (scRNA-seq) datasets and combined it with ex vivo OPC cultures and in vivo cell transplantation experiments. This approach revealed the emergence of "angiogenic" OPCs in the subacute phase and "oligogenic" OPCs in the chronic phase, driven by distinct levels of hypoxia-severe hypoxia inducing angiogenic OPCs and mild hypoxia promoting oligogenic OPCs. Ex vivo, severe hypoxic preconditioning faithfully induced angiogenic OPCs, and their intravenous transplantation enhanced angiogenesis and improved recovery in tMCAO mice. These findings highlight "oxygen tone" as a key regulator of OPC dynamic adaptation after ischemic stroke, offering a promising strategy to harness OPCs for stroke cell therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.